Oura has moved into the public phase of its U.S. initial public offering, filing to list shares on the Nasdaq Global Select Market under the ticker OURA with an indicated price range of $40 to $44 per share. The wearable-health company plans to sell 50 million shares, according to its latest registration statement, placing the proposed offering at roughly $2 billion to $2.2 billion before underwriting fees if all shares are sold within that range.
The filing gives public markets their first formal benchmark for valuing Oura ahead of its debut. It also draws a clearer dividing line between the company’s planned Nasdaq listing and a separate derivatives contract tied to expectations around its pre-listing value.
Oura, known for its Oura Ring biometric wearable, sells hardware alongside paid memberships through its mobile app. The ring is designed to track measures including sleep, activity, recovery, stress, cardiovascular signals and temperature trends. That combination gives Oura exposure to consumer device demand while adding recurring subscription revenue that can continue after the initial ring purchase.
The final IPO price has not been set and could land outside the stated range before shares begin trading. The registration statement also says the offering will include both newly issued shares and stock sold by existing holders, meaning the gross value of the sale should not be treated as money flowing entirely to Oura.
Newly issued shares would raise capital for the company, while secondary shares sold by current holders would provide liquidity to those selling owners. The filing does not make an indicated price range a guarantee of the final valuation or confirm how the offering proceeds will ultimately be divided between the company and selling shareholders.
IPO pricing and derivatives use different mechanisms
A pre-listing derivatives product linked to Oura expectations has appeared alongside the IPO process, but it does not represent ownership of Oura stock. Holders of the contract do not receive shareholder voting rights, dividends, IPO allocations or other rights attached to Nasdaq-listed equity.
Its market price is determined by buying and selling interest in that derivatives market, rather than by the book-building process used by the IPO’s underwriters. Book-building is the process through which banks gather indications of demand from prospective share buyers and use that information to help set an IPO price and allocate shares.
That difference means the derivative can trade above or below Oura’s $40-to-$44 indicated IPO range without changing the terms of the share offering. A move in the derivatives contract may reflect changing expectations, short-term positioning or limited liquidity in that market; it does not by itself show that Oura has raised or lowered its planned IPO price.
The relationship could become especially unstable as the transaction approaches pricing. Amendments to the prospectus, a change in the number of shares offered, revised marketing demand or details around the first day of trading could all alter expectations in the derivative market. Broader market variables—including interest-rate expectations, technology-sector valuations, consumer spending trends and performance by comparable consumer-health businesses—could also influence pricing.
Oura’s eventual stock price will be formed separately once the company begins regular Nasdaq trading. At that point, publicly traded OURA shares would become the main real-time market reference for the company’s valuation, replacing pre-listing estimates and private-market comparisons as the most visible benchmark.
Subscription model raises the focus on membership retention
The IPO filing places Oura’s business model under closer public scrutiny because the company combines a consumer hardware product with recurring membership fees. Hardware companies can face uneven sales cycles tied to product launches, replacement demand and consumer budgets. Membership revenue could provide a more predictable component if users remain active after buying a ring.
That model also makes several operating measures central to how public-market participants assess the business. Revenue growth, profitability, membership expansion, ring sales, product releases and international growth could all influence demand for the shares. Competition in wearables and digital health adds another variable, particularly if rival devices offer similar tracking features or compete for the same health-conscious consumers.
The $40-to-$44 range provides a visible starting point for those assessments, though it should not be read as a settled market judgment. IPO ranges can change before pricing, particularly if demand during the marketing period differs from expectations or market conditions move sharply.
Oura’s public filing also gives potential share buyers a more standardized source of information than the private-market marks that previously shaped much of the discussion around the company’s value. Private-company valuations can vary by financing round, preferred-share terms and negotiated transactions. A registered IPO introduces a proposed common-share price that can be compared more directly with other listed consumer technology and digital-health businesses.
Trading begins after pricing, not after speculation
The proposed Nasdaq listing would allow Oura shares to trade publicly only after the offering is priced and the stock begins regular-market trading. The derivative contract remains a separate instrument governed by its own product rules, including any terms addressing a transition after OURA begins trading.
Pre-listing derivative prices may offer a rough view of market sentiment, but they are not a substitute for the IPO allocation process or for a publicly traded share price. Contracts can be influenced by supply-demand imbalances that have little connection to the final number of shares allocated by underwriters.
For Oura, the IPO will test how public-market buyers value a premium health wearable company whose revenue depends on both device demand and ongoing memberships. The initial range establishes the first official price framework for that test, while the final result will depend on the offering’s pricing process and the market’s response once OURA starts trading on Nasdaq.
Want to trade pre-IPO style price moves? Explore stock-linked derivatives on Toobit’s event contracts platform.
Disclaimer: The content on this page is provided for general informational purposes only and does not represent the views or financial advice of Toobit. We make no guarantees regarding the accuracy or completeness of this information and shall not be held liable for any errors, omissions, or outcomes resulting from its use. Investing in digital assets involves risk; users should independently evaluate their financial situation and the risks involved. For further details, please consult our Terms of Service and Risk Disclosure.
